Natural History of Amyloid Deposition in Adults With Down Syndrome

University of Pittsburgh81 enrolled

Overview

The primary objective of this study is to assess the presence of amyloid in non-demented/functionally stable adults with DS as a function of age, dividing the sample into amyloid-positive and amyloid-negative groups. We will also obtain baseline cognitive measures across a range of areas that are often affected by AD.

Specific Aim 1: To assess and compare amyloid deposition (with PiB PET) in non-demented/functionally stable adults with DS across three age cohorts (30-39, 40-49, and \>50 years of age). Primary Hypothesis 1: At initial assessment, there will be a significantly higher prevalence of amyloid-positive (PiB+) subjects in each succeeding age cohort. In addition, we will test the following secondary hypothesis: Secondary Aim 1: To compare the presence or absence of the apolipoprotein-E4 allele to the retention of PiB in various brain areas of the DS subjects. Secondary Hypothesis 1: At baseline, subjects who carry at least one Apolipoprotein-E4 (ApoE4) allele will show a higher prevalence of being PiB+.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Down Syndrome

Eligibility

Sex: ALLMin age: 30 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Participant IQ at least 47 (based upon Stanford-Binet V Abbrev. Test Battery) 2. Participant at least 30 years of age 3. DSDS score indicating participant is asymptomatic for AD 4. Reliable caregiver who is capable of providing correct information about the participant's clinical symptoms and history 5. Agreement of caregiver and clinician that participant is able to cooperate with the protocol tasks 6. Participant has provided assent (or consent) and/or parent/caregiver has provided informed consent Exclusion Criteria: 1. Participant is non-verbal or has extremely limited language skills 2. Score within the "symptomatic" range on the DSDS 3. Any significant disease or unstable medical condition that could affect neuropsychological testing 4. Any problems with vision or hearing that could affect neuropsychological testing 5. Participants in whom MRI is contraindicated 6. Claustrophobia or prior failed experiences of completing MRI scans or blood draws 7. Participant is pregnant or breast feeding 8. History or other evidence of severe illness or other condition that would make the participant, in the opinion of the investigator, unsuitable for the study?

Locations (2)

University of Pittsburgh and University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Waisman Center at the University of Wisconsin - Madison

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

Amyloid deposition

Obtained via PiB PET scan

Time frame: every 36 months for 9 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.